Inovio Pharmaceuticals is trading at $1.17, up 5.39%, alongside broader-market strength attributed to cooler-than-expected inflation data and lower Treasury yields.
- The S&P 500 and Nasdaq Composite are also higher.
- No new company-specific announcement explaining the move was found. The latest major company news remains the FDA review of INO-3107, with an October 30 target date.